P01.071 Genomic profiling identifies tubulin mutations that may predict response to depatuxizumab mafodotin in patients with glioblastoma

BACKGROUND: Depatuxizumab mafodotin (depatux-m) is an antibody-drug conjugate (ADC) composed of an EGFR-targeted antibody conjugated to a microtubule inhibitor warhead, monomethyl auristatin F. In a Phase 1 study in glioblastoma (GBM), selection for EGFR amplification (amp) enriched for patients (pt...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Lassman, A B, Roberts-Rapp, L, He, L, Lu, X, Zha, Z, Bhathena, A, Ansell, P J, Gan, H K, Scott, A M, van den Bent, M
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2018
Matèries:
Poster Presentations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6144056/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy139.113
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars